Overview

* WW fiscal Q2 rev declines 6% yr/yr, Clinical rev grows 55%

* Co completes strategic reorganization, reduces debt by $1.15 bln

* Predecessor net income margin impacted by reorganization items in fiscal Q2

Outlook

* Company projects full-year revenue of $685 mln to $700 mln

* WW International ( WW ) expects adjusted EBITDA of $140 mln to $150 mln

* Company cites ongoing challenges in behavioral business impacting revenue

Result Drivers

* DEBT REDUCTION - Co completed strategic reorganization, reducing debt by $1.15 bln

* CLINICAL GROWTH - Clinical revenues rose 55% yr/yr, driven by compounded semaglutide subscriptions

* BEHAVIORAL CHALLENGES - Revenue decline attributed to ongoing headwinds in behavioral business

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $189 mln

Revenue

Q2 Net $1.19

Income bln

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)